Document:

EXHIBIT
10.2

 

CONSULTING
AND CONFIDENTIALITY AGREEMENT

 

This
CONSULTING AND CONFIDENTIALITY AGREEMENT (this “Agreement”) is entered into as of April 20, 2020 (the
“Effective Date”), by and between IGL Pharma, Inc., a Delaware corporation (“IGL Pharma”)
and QSAM Therapeutics Inc., a Texas corporation (“QSAM”).

 

WHEREAS,
capitalized terms used herein and not otherwise defined shall have the meaning ascribed to such terms in that certain Patent and
Technology License Agreement and Trademark Assignment dated April 20, 2020 between IGL Pharma and QSAM (the “License
Agreement”);

 

WHEREAS,
in connection with the License Agreement, the parties agree that IGL Pharma shall provide consultancy and advisory services related
to its grant to QSAM of an exclusive license under Patents and Product Data for a period of time limited and defined herein (the
“Consultancy”) to assist QSAM with commercialization of the Product; and

 

WHEREAS,
as part of the Consultancy, QSAM is willing to disclose Confidential Information (as defined below) to IGL Pharma, and IGL Pharma
is willing and agrees to receive such information on a confidential basis in accordance with the terms of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein, QSAM and IGL Pharma hereby agree to be legally bound as
follows:

 

1.
Nature and Scope of Consultancy. IGL Pharma will provide Consultancy, as reasonably requested by QSAM, through assisting
and advising QSAM with scientific and manufacturing support, and other areas. The parties agree that R. Keith Frank and Jaime
Simón, principals of IGL Pharma, will be providing the Consultancy services to QSAM. On the first day of each month commencing
sixty days after the Effective Date of the License Agreement and then for the following twenty-four (24) months, QSAM agrees to
compensate IGL Pharma $8,500 for Consultancy services performed pursuant to this Agreement.

 

The
parties hereto expect that all activities conducted by IGL Pharma as part of the Consultancy will take place at IGL Pharma’s
places of business or at locations chosen by IGL Pharma for its own convenience and that all non-written communication will be
through teleconference and WebEx.

 

For
avoidance of doubt, nothing contained within this Agreement shall impose an obligation of exclusivity on one party by the other.
Both parties reserve the right to enter into and participate in other activities (either alone or with a third party) including
QSAM seeking consultancy from other external consultants, advisors and/or representatives.

 

2.
Confidential Information. The term “Confidential Information” shall have the meaning as set forth
in the License Agreement and Article 8 of the License Agreement is hereby incorporated by reference in its entirety.

 

3.
Inventions. IGL Pharma acknowledges that any and all inventions, products, designs, drawings, notes, documents, information,
documentation, improvements, works of authorship, processes, techniques, know-how, algorithms, specifications, biological or chemical
specimens or samples, and other materials of any kind (collectively known as “Inventions”) conceived
or originated by IGL Pharma with the use of the Confidential Information in the course of providing Consultancy shall be assigned
to QSAM and remain the exclusive property of QSAM. IGL Pharma hereby assigns and agrees to take all actions to assign to QSAM
all of IGL Pharma’s right, title and interest in and to any Invention. QSAM is under no obligation to use or otherwise exploit
such Inventions, and QSAM is under no obligation to compensate IGL Pharma for such Inventions. IGL Pharma does not convey to QSAM
any interest in any idea or invention other than Inventions.

 

    	 	Page
                                         1
                                         of 6	 

    	 	 	 

    

 

4.
Term and Termination. The provisions of this Agreement shall take effect upon execution of the License Agreement, and the
contemporaneous execution of this Agreement, by all parties and shall continue for a period of twenty-four (24) months, including
the period that covers the final payment hereunder, or as extended by the parties. This Agreement shall terminate immediately,
and without any notice from either party, upon termination of the License Agreement for whatever reason.

 

5.
Indemnification; Disclaimer of Liability.

 

(i)
IGL Pharma shall indemnify, defend and hold QSAM, its Affiliates and their respective officers, directors, employees and agents
(each, an “Indemnified Party”) harmless from and against any and all third party claims, liabilities,
lawsuits, threats of lawsuits or other governmental action, or losses suffered, incurred or sustained by any Indemnified Party,
by reason of any action to the extent arising out of: (a) IGL Pharma’s material breach of this Agreement, including any
breach of a representation or warranty made by IGL Pharma under this Agreement; (b) any negligent act or willful misconduct on
the part of IGL Pharma, Affiliates of IGL Pharma, subcontractors of IGL Pharma, or its or their respective employees or agents
in performing any obligations under this Agreement; or (c) any assertion that IGL Pharma is not an independent contractor. Notwithstanding
the foregoing, IGL Pharma shall not be liable for losses to the extent such losses are caused by the gross negligence or willful
misconduct of QSAM.

 

(ii)
QSAM shall indemnify, defend and hold IGL Pharm, its Affiliates and their respective officers, directors, employees and agents
(each, an “Indemnified Party”) harmless from and against any and all third party claims, liabilities,
lawsuits, threats of lawsuits or other governmental action, or losses suffered, incurred or sustained by any Indemnified Party,
by reason of any action to the extent arising out of: (a) QSAM’s material breach of this Agreement; (b) any negligent act
or willful misconduct on the part of QSAM, Affiliates of QSAM, subcontractors of QSAM, or its or their respective employees or
agents in performing any obligations under this Agreement; or (c) any assertion that QSAM is not an independent contractor. Notwithstanding
the foregoing, IGL Pharma shall not be liable for losses to the extent such losses are caused by the gross negligence or willful
misconduct of QSAM.

 

(iii)
IN NO EVENT SHALL ANY PARTY BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION,
DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF,
OR IN CONNECTION WITH, THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER THE PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY
OF SUCH DAMAGES.

 

6.
General.

 

    	 	Page
                                         2
                                         of 6	 

    	 	 	 

    

 

(i)
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered in
person, mailed by a reputable overnight courier (return receipt requested), or mailed by certified U.S. mail (return receipt requested)
to the parties at the following addresses, or at such other addresses as shall be specified by the parties by like notice:

 

If
to QSAM:

 

QSAM
Therapeutics Inc.

Attn:
Chief Executive Officer

3616
Far West Blvd., Suite 117-292

Austin,
TX 78731

 

If
to IGL Pharma:

 

IGL
Pharma Pharmaceuticals, Inc.

Attn:
Chief Executive Officer

1004
Velasco Street

Angleton,
TX 77515

 

(ii)
This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto.

 

(iii)
Failure or delay by either party in exercising or enforcing any provision, right, or remedy under this Agreement, or waiver of
any remedy hereunder, in whole or in part, shall not be deemed a waiver thereof, or prevent the subsequent exercise of that or
any other rights or remedy.

 

(iv)
This Agreement may not be assigned or otherwise transferred by either party hereto without the prior written consent of the other
party; provided, however, that either party may assign this Agreement, without the consent of the other party, (a) to any of its
Affiliates, if the assigning party unconditionally guarantees the full performance of such Affiliate’s obligations hereunder
or (b) in connection with such party’s merger, consolidation or transfer or sale of all or substantially all of the assets
of such party to which this Agreement relates, provided, that the successor, surviving entity, purchaser of assets, transferee,
or other similar party, as applicable, expressly assumes in full in writing such party’s obligations under this Agreement.
Any purported assignment in contravention of this Section 6(iv) shall, at the option of the non-assigning party, be null and void
and of no effect. No assignment shall release either party from responsibility for the performance of any accrued obligation of
such party hereunder. This Agreement shall be binding upon and enforceable against the successor to or any permitted assignees
from either of the parties hereto.

 

(v)
All expenses, including the fees of any attorneys, accountants, or others engaged by a party, incurred in connection with the
negotiation and execution of this Agreement and the transactions contemplated hereby and thereby, shall be paid by the party incurring
such expenses.

 

(vi)
If there is any conflict between the provions of this Agreement and the License Agreement, the provisions in the License Agreement
will control.

 

    	 	Page
                                         3
                                         of 6	 

    	 	 	 

    

 

(vii)
This Agreement, including the validity, construction, interpretation and performance thereof, shall be governed entirely by the
laws of the State of Delaware, without regard to its conflict of laws provisions.

 

(viii)
If any dispute or disagreement arises between IGL Pharma and QSAM in respect of this Agreement, it will be settled as set forth
in Section 13.2 of the License Agreement, said Section 13.2 being hereby incorporated by reference in its entirety.

 

(ix)
If any provisions of this Agreement shall be held to be illegal, invalid, or unenforceable under any applicable law, then such
contravention or invalidity shall not invalidate the entire Agreement. Such provision shall be deemed to be modified to the extent
necessary to render it legal, valid, and enforceable, and if no such modification shall render it legal, valid and enforceable,
then this Agreement shall be construed as if not containing the provision held to be invalid, and the rights and obligations of
the parties shall be construed and enforced accordingly.

 

(x)
The headings in the Agreement are for convenience only and will not be deemed to affect in any way the language of the provisions
to which they refer.

 

(xi)
No provision of this Agreement shall be deemed or construed in any way to result in the creation of any rights or obligations
in any person or entity not a party to this Agreement.

 

(xii)
Neither party shall be held in breach of this Agreement for failure to perform any of its obligations hereunder to the extent
and for the time period such performance is prevented in whole or in part by reason of any Force Majeure event, including but
not limited to industrial disputes, strikes, lockouts, riots, mobs, fires, floods, pandemics, and other natural disasters and
Acts of God, wars declared or undeclared, civil strife, embargo, delays in delivery or defects or shortages of raw materials from
suppliers, loss or breakdown of any production equipment, losses or shortage of power, damage to or loss of goods in transit,
currency restrictions, or events caused by reason of laws, regulations or orders by any government, governmental agency or instrumentality
or by any other supervening unforeseeable circumstances whatsoever beyond the control of the party so affected. The party so affected
shall (a) give prompt written notice to the other party of the nature and date of commencement of the Force Majeure event and
its expected duration; and (b) use its commercially reasonable efforts to avoid or remove the Force Majeure event as soon as possible
to the extent it is so able to do so.

 

(xiii)
Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a)
“include”, “includes” and “including” are not limiting and mean include, includes and including,
without limitation; (b) definitions contained in this Agreement are applicable to the singular as well as the plural forms of
such terms; (c) references to an agreement, statute or instrument mean such agreement, statute or instrument as from time to time
amended, modified or supplemented; (d) references to a person are also to its permitted successors and assigns; (e) references
to an “Article”, “Section”, “Exhibit” or “Schedule” refer to an Article or Section
of, or any Exhibit or Schedule to, this Agreement unless otherwise indicated; (f) the word “will” shall be construed
to have the same meaning and effect as the word “shall”; and (g) the word “any” shall mean “any
and all” unless otherwise indicated by context. The parties to this Agreement further agree that it was negotiated fairly
between them at arms’ length and that the final terms of this Agreement shall be deemed to have been jointly and equally
drafted by them, and that the provisions of this Agreement therefore should not be construed against a party to it on the grounds
that the party drafted or was more responsible for drafting the provision(s).

 

    	 	Page
                                         4
                                         of 6	 

    	 	 	 

    

 

(xiv)
IGL Pharma shall be acting as an independent contractor in performing the Consultancy and shall not be considered or deemed an
agent, employee, joint venturer, or partner of QSAM. Neither party shall have, or shall represent that it has, any power, right
or authority to bind the other party to any obligation or liability, or to assume or create any obligation or liability on behalf
of the other party.

 

(xv)
IGL Pharma represents and warrants to QSAM that it will not use in any capacity the services of any person or entity debarred
under subsections 306(a) or (b) of the Federal Food, Drug, and Cosmetic Act to perform any of the Consultancy services.

 

(xvi)
This Agreement may be executed in one or more counterparts which together shall constitute a single agreement. Copies of executed
counterparts transmitted by facsimile or other electronic transmission means shall be considered original executed counterparts
for purposes of this Section 6(xvii).

 

[Signature
Page Follows]

 

    	 	Page
                                         5
                                         of 6	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the Effective Date.

 

	QSAM
    Therapeutics Inc.	 	IGL
    Pharma, Inc.
	 	 	 	 	 
	 	/s/
    Douglas Baum	 	 	/s/
    C. Richard Piazza
	Name:	Douglas
    Baum	 	Name:	C.
    Richard Piazza, PhD
	Title:	CEO	 	Title:	President
    & CEO

 

    	 	Page
                                         6
                                         of 6Exhibit

Exhibit 4.2
 
DESCRIPTION OF THE REGISTRANT’S SECURITIES 
REGISTERED PURSUANT TO SECTION 12 OF THE 
SECURITIES EXCHANGE ACT OF 1934 
 
As of December 31, 2019, the sole class of securities of Apogee Enterprises, Inc. (the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended, was the Company’s common stock.
 
DESCRIPTION OF COMMON STOCK
 
The following description of the Company’s common stock is only a summary and does not purport to be complete and is qualified by reference to the Company’s Restated Articles of Incorporation (the “Articles”) as amended, and the Amended and Restated Bylaws (the “Bylaws”). The Articles and Bylaws have been incorporated by reference as exhibits to the Company’s most recent Annual Report on Form 10-K.
 
The Company’s Articles authorize the issuance of 50,000,000 shares including the Company’s common stock, par value $0.33 1/3 per share (the “Common Stock”) and preferred stock, of which 200,000 shares have been designated as Series A Junior Preferred Stock, par value $1.00 per share. As of April [•], 2020, there were no shares of preferred stock outstanding.
 
Common Stock
 
The holders of Common Stock are entitled to one vote for each share held of record on all matters voted upon by shareholders and may not cumulate votes for the election of directors. Accordingly, the holders of a majority of the shares of Common Stock outstanding will be able to elect all of the directors. The holders of Common Stock are entitled to such dividends as may be declared by the Board of Directors. Subject to the preferential rights, if any, of any class or series of the undesignated shares that may be authorized and issued by the Board of Directors, each share of outstanding Common Stock is entitled to participate equally in any distribution of net assets made to the shareholders in liquidation of the Company. There are no redemption, sinking fund, conversion or preemptive rights with respect to the shares of Common Stock. All shares of Common Stock have equal rights and preferences.
 
Preferred Stock
 
The Company’s Articles provide that shares of preferred stock may be issued by the Board of Directors from time to time, in one or more series, having such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof or other privileges as it may establish. The issuance of preferred stock by the Board of Directors could affect the rights of holders of Common Stock. For example, issuance of the preferred stock could result in a class of securities outstanding that will have preferences with respect to dividends and in liquidation over the Common Stock, and could (upon conversion or otherwise) enjoy all of the rights appurtenant to Common Stock. The Company has no current plans to issue any preferred stock.
 
Certain Charter and Bylaws Provisions
 
The Company’s Articles and Bylaws contain certain “anti- takeover” provisions that could have the effect of delaying or preventing certain changes in control of the Company and thereby deprive shareholders of an opportunity to sell their shares at a premium over prevailing market prices.
 
The Company’s directors are elected for three year, staggered terms, such that only a portion of the Company’s directors are elected in any year. This provision of the Bylaws, together with a provision discussed below that is contained in the Articles and governs removal of directors, could have the effect of delaying for a period of two years or more a change in control of the Company by delaying a potential acquirer’s ability to elect a majority of the Board of Directors, depending upon the number of directors next up for election following any such acquisition. Cumulative voting of shares in the election of directors is prohibited.
 
The Company’s Articles require that certain “Business Combinations” (as defined in the Articles), including mergers, consolidations and sales of a substantial amount of assets, between the Company or a majority-owned subsidiary of the Company and an “Interested Stockholder” (as defined in the Articles) or its affiliates or associates, be approved by the affirmative vote of the holders of at least 80% of the outstanding shares of voting stock of the Company, unless such Business Combination shall have been approved by a majority of “Disinterested Directors” (as defined in the Articles) or shall satisfy certain fair price and other conditions. In such event, a Business Combination, in order to be approved, requires only such affirmative vote as may be required by law, any other provision of the Articles or the terms of any other securities of the Company. 

The Company’s Articles generally provide that, except as otherwise prohibited by Minnesota law, no director of the Company shall be personally liable to the Company or its shareholders for monetary damages for any breach of fiduciary duty by such a person in the capacity of a director. The Company’s Bylaws provide for indemnification of the Company’s officers, directors, employees, and agents to the fullest extent permitted by law.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]